Todays Report: The TNB Financial decides to keep it stake in Pfizer Inc. (PFE) to the level of $1,732,000

The TNB Financial decides to keep it stake in Pfizer Inc. (PFE) to the level of $1,732,000

TNB Financial raised its position in Pfizer Inc. (NYSE:PFE) by 59.1% during the second quarter, Holdings Channel reports. The firm owned 49,193 shares of the biopharmaceutical company’s stock after buying an additional 18,265 shares during the period. TNB Financial’s holdings in Pfizer were worth $1,732,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Ronna Sue Cohen raised its position in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 35 shares during the period. Forte Capital LLC ADV raised its position in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 36 shares during the period. Naples Global Advisors LLC raised its position in shares of Pfizer by 0.4% in the second quarter. Naples Global Advisors LLC now owns 24,327 shares of the biopharmaceutical company’s stock worth $857,000 after buying an additional 85 shares during the period. Capital Asset Advisory Services LLC raised its position in shares of Pfizer by 0.5% in the second quarter. Capital Asset Advisory Services LLC now owns 21,259 shares of the biopharmaceutical company’s stock worth $749,000 after buying an additional 100 shares during the period. Finally, Hartford Financial Management Inc. raised its position in shares of Pfizer by 1.4% in the second quarter. Hartford Financial Management Inc. now owns 7,221 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 100 shares during the period. Institutional investors own 69.66% of the company’s stock.

Shares of Pfizer Inc. (NYSE:PFE) traded down 0.94% during midday trading on Thursday, hitting $32.76. The company’s stock had a trading volume of 24,181,890 shares. The company has a market cap of $198.71 billion, a P/E ratio of 29.04 and a beta of 0.86. The company has a 50-day moving average price of $34.14 and a 200 day moving average price of $34.26. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same quarter last year, the company posted $0.56 EPS. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.66%. Pfizer’s dividend payout ratio is currently 95.24%.

A number of analysts have recently issued reports on the company. Argus restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Sunday, August 28th. Jefferies Group cut Pfizer from a “buy” rating to a “hold” rating and set a $36.00 price objective on the stock. in a research report on Thursday. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Vetr cut Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective on the stock. in a research report on Tuesday, June 28th. Finally, Citigroup Inc. restated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research report on Wednesday, August 3rd. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $38.66.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment